Residency · Residency · Medical Genetics Genomics
Urea Cycle Defects: Diagnosis and Acute Management
Overview
The urea cycle is the primary pathway for nitrogen disposal, converting ammonia to urea in the liver. Deficiency of any of the six enzymes or two transporters in the cycle causes hyperammonemia. The combined incidence is approximately 1 in 30,000-35,000 live births, with ornithine transcarbamylase (OTC) deficiency being the most common (X-linked, approximately 1 in 56,000). Presentation ranges from neonatal hyperammonemic coma to late-onset episodic hyperammonemia. Untreated severe neonatal hyperammonemia causes irreversible brain damage and death, making rapid diagnosis and treatment critical emergencies.
Enzymology of the Urea Cycle
Cycle Steps and Associated Disorders
The cycle begins with carbamyl phosphate synthetase I (CPS1), which converts ammonia, bicarbonate, and ATP to carbamyl phosphate in the mitochondrial matrix; CPS1 deficiency is autosomal recessive with frequently severe neonatal presentation and requires N-acetylglutamate (NAG) as an allosteric activator. NAG is produced by N-acetylglutamate synthase (NAGS); NAGS deficiency is autosomal recessive and uniquely treatable with carglumic acid (N-carbamylglutamate). Ornithine transcarbamylase (OTC) converts carbamyl phosphate plus ornithine to citrulline in the mitochondria; OTC deficiency is X-linked and the most common UCD. Argininosuccinate synthetase (ASS1) converts citrulline plus aspartate to argininosuccinate in the cytoplasm; deficiency causes citrullinemia type I. Argininosuccinate lyase (ASL) cleaves argininosuccinate to arginine plus fumarate; deficiency causes argininosuccinic aciduria, the most common UCD detectable by NBS. Arginase 1 (ARG1) converts arginine to urea plus ornithine; deficiency causes argininemia with a distinct spastic diplegia phenotype. Additionally, defects in the mitochondrial ornithine transporter (ORNT1/SLC25A15) cause HHH syndrome, and citrin (SLC25A13) deficiency causes neonatal intrahepatic cholestasis and adult-onset citrullinemia type II.
<image>Diagram of the urea cycle showing all six enzymatic steps and two transporters, with mitochondrial and cytoplasmic compartments labeled, and the specific enzyme deficiency causing each urea cycle disorder highlighted</image>
Clinical Presentation
Neonatal (Severe) Onset
Severe neonatal presentation typically occurs at 24-72 hours of life after initiation of protein feeds. Initial symptoms include poor feeding, irritability, vomiting, and tachypnea (central hyperventilation from ammonia stimulation of the respiratory center). Progression leads to lethargy, hypothermia, seizures, and coma. Laboratory findings include hyperammonemia (often exceeding 1,000 micromol/L in neonatal crisis), respiratory alkalosis (early, due to central hyperventilation -- the key distinguishing feature from organic acidemias which present with metabolic acidosis), normal glucose initially, normal anion gap, and elevated glutamine on plasma amino acids.
Late-Onset Presentation
Partial enzyme deficiency allows some residual urea cycle function, and presentation may occur at any age including adulthood. Triggers include catabolic stress from illness, surgery, high-protein meals, the postpartum period, or corticosteroids. Symptoms include recurrent vomiting, behavioral changes, confusion, ataxia, psychiatric symptoms, and lethargy progressing to coma. The condition may be misdiagnosed as Reye syndrome, psychiatric disease, or encephalitis. OTC deficiency in heterozygous females shows variable phenotype due to X-inactivation patterns, ranging from asymptomatic carrier to fatal neonatal presentation (rare).
Specific Clinical Features by Disorder
CPS1 and OTC deficiency show elevated ammonia with low citrulline, distinguished by urine orotic acid (elevated in OTC, normal or low in CPS1). Citrullinemia type I (ASS1) produces massively elevated citrulline, often exceeding 1,000 micromol/L. Argininosuccinic aciduria (ASL) shows moderately elevated citrulline plus argininosuccinic acid in plasma and urine, along with trichorrhexis nodosa (brittle hair). Argininemia (ARG1) shows elevated arginine and presents with progressive spastic diplegia rather than acute hyperammonemia. NAGS deficiency is clinically identical to CPS1 deficiency but specifically treatable with carglumic acid.
| Disorder | Gene | Inheritance | Key Biochemical Marker | Distinguishing Feature | Specific Treatment |
|---|---|---|---|---|---|
| CPS1 deficiency | CPS1 | AR | Low citrulline; normal orotic acid | Cannot be distinguished from NAGS without genetic testing | Nitrogen scavengers |
| NAGS deficiency | NAGS | AR | Low citrulline; normal orotic acid | Identical to CPS1 clinically | Carglumic acid (specific cure) |
| OTC deficiency | OTC | X-linked | Low citrulline; elevated urine orotic acid | Most common UCD; variable in females | Nitrogen scavengers; liver transplant |
| Citrullinemia type I | ASS1 | AR | Very high citrulline (>1,000 μmol/L) | Detectable by NBS | Nitrogen scavengers; arginine supplementation |
| Argininosuccinic aciduria | ASL | AR | Elevated citrulline + argininosuccinic acid | Trichorrhexis nodosa; NBS-detectable | Nitrogen scavengers; arginine supplementation |
| Argininemia | ARG1 | AR | Elevated arginine | Spastic diplegia (not typical hyperammonemia) | Low-protein diet; nitrogen scavengers |
Diagnostic Workup
Emergency Labs
Ammonia must be collected on ice and run immediately because it rises in improperly handled samples. Blood gas reveals respiratory alkalosis (early) or mixed acidosis (late/severe). Plasma amino acids identify the specific enzyme defect: low citrulline points to CPS1, OTC, or NAGS deficiency; very high citrulline indicates ASS1 deficiency; moderate citrulline plus argininosuccinic acid indicates ASL deficiency; high arginine indicates ARG1 deficiency; and high glutamine is present in all UCDs. Urine organic acids show elevated orotic acid in OTC deficiency (carbamyl phosphate diverted to the pyrimidine synthesis pathway), making urine orotic acid the key test distinguishing OTC from CPS1 and NAGS deficiency.
Confirmatory Testing
Molecular testing (gene-specific or UCD gene panel) is essential for confirming diagnosis, genetic counseling, and carrier testing. Liver biopsy for enzyme activity (historically used for CPS1 and OTC) has been largely replaced by molecular testing. The allopurinol loading test can elevate urinary orotidine in OTC carrier females but has limited sensitivity.
<image>Diagnostic algorithm for hyperammonemia in the neonate, showing stepwise evaluation from ammonia level through blood gas, plasma amino acids, and urine organic acids/orotic acid to identify the specific urea cycle defect</image>
Acute Management of Hyperammonemic Crisis
Immediate Actions (First 1-2 Hours)
All protein intake is stopped immediately. IV dextrose (D10 at 1.5 times maintenance) plus intralipid (2-3 g/kg/day) provides calories and suppresses catabolism. Ammonia scavenger therapy with Ammonul (sodium phenylacetate plus sodium benzoate IV) is initiated with a loading dose of 250 mg/kg each over 90-120 minutes followed by maintenance of 250 mg/kg/day each as continuous infusion. Phenylacetate conjugates with glutamine (excreted as phenylacetylglutamine), and benzoate conjugates with glycine (excreted as hippurate). Arginine HCl IV (200-600 mg/kg loading dose) provides substrate for the urea cycle and promotes waste nitrogen excretion, except in ARG1 deficiency where citrulline is used instead. N-carbamylglutamate (carglumic acid) specifically treats NAGS deficiency and is used empirically pending diagnosis. Hemodialysis (preferably continuous venovenous hemodialysis) is the most effective method for rapid ammonia clearance, indicated when ammonia exceeds 500 micromol/L, is not responding to medical therapy within 4-8 hours, or is rising despite treatment. Peritoneal dialysis and exchange transfusion are ineffective for ammonia clearance.
Goals of Acute Management
The goal is to reduce ammonia below 200 micromol/L as rapidly as possible. Duration of hyperammonemia correlates with neurological outcome. Ammonia exceeding 300-500 micromol/L for more than 24 hours carries high risk of severe brain damage. Neonates with peak ammonia above 1,000 micromol/L have very poor neurological prognosis.
Long-Term Management
Dietary Management
Protein restriction is individualized to the minimum needed for growth (typically 1.0-1.5 g/kg/day in infants). Essential amino acid supplementation is provided if dietary intake is insufficient. Prolonged fasting must be avoided and adequate caloric intake ensured to prevent catabolism. Emergency "sick day" protocols are provided to all families.
Chronic Medications
Oral ammonia scavengers for daily use include sodium phenylbutyrate (Buphenyl) and glycerol phenylbutyrate (Ravicti), the latter offering liquid formulation with better palatability and more consistent drug levels. L-citrulline supplements OTC and CPS1 deficiency by providing substrate for ASS1 and ASL to continue the cycle. L-arginine supplements ASS1 and ASL deficiency where arginine becomes conditionally essential. Carglumic acid provides specific chronic therapy for NAGS deficiency.
Liver Transplantation
Liver transplantation is the definitive treatment, correcting hepatic enzyme deficiency. It is recommended for severe neonatal-onset UCDs, especially OTC, CPS1, and ASS1 deficiency, typically performed between 3-12 months of age if medically stabilized. Post-transplant, dietary restriction and ammonia scavengers are discontinued, though pre-existing neurological damage is not reversed. Living-related donors must be confirmed as non-carriers for OTC (asymptomatic female carriers may have insufficient hepatic OTC activity). For ASL deficiency, liver transplant corrects hyperammonemia but may not prevent all complications, as ASL has extra-hepatic functions including nitric oxide metabolism, and neurocognitive issues may persist.
OTC Deficiency in Heterozygous Females
Variable Phenotype
X-inactivation patterns determine clinical severity. Most carrier females are asymptomatic but may be at risk for hyperammonemia during catabolic stress (illness, postpartum, surgery). Some have protein aversion, headaches, or subclinical cognitive deficits. Rarely, severe neonatal presentation occurs due to skewed X-inactivation favoring the mutant allele.
Identification and Monitoring
Carrier testing uses molecular methods (OTC gene sequencing/deletion analysis). The allopurinol loading test showing elevated urinary orotidine has approximately 80% sensitivity. Carrier females should have emergency protocols, avoid prolonged fasting, and be monitored during catabolic events. Genetic counseling notes that 50% of sons will be affected and 50% of daughters will be carriers.
<image>Clinical spectrum of OTC deficiency showing the range from severe neonatal presentation in hemizygous males through variable manifestations in heterozygous females, with the influence of X-inactivation patterns on phenotype</image>
Clinical Pearls
Respiratory alkalosis in a sick neonate with elevated ammonia is the hallmark of urea cycle defects -- this distinguishes UCDs from organic acidemias, which cause metabolic acidosis with hyperammonemia. Urine orotic acid is the key test to distinguish OTC deficiency (elevated) from CPS1 and NAGS deficiency (normal/low) -- all three present with low citrulline. NAGS deficiency is the only UCD with a specific pharmacological cure (carglumic acid) -- this diagnosis should always be considered in a hyperammonemic neonate with low citrulline. Peak ammonia level and duration of hyperammonemia are the strongest predictors of neurological outcome, and dialysis should not be delayed. Late-onset OTC deficiency can present for the first time in adulthood, including in the postpartum period -- any unexplained encephalopathy should prompt ammonia measurement. Living-related liver donors for OTC patients must be tested for carrier status, as asymptomatic female carriers may have insufficient hepatic OTC activity for safe donation. Argininosuccinic aciduria (ASL deficiency) is unique among UCDs: liver transplant corrects hyperammonemia, but neurocognitive issues and trichorrhexis nodosa may persist due to extra-hepatic ASL functions.
References
- Ah Mew N, Simpson KL, Gropman AL, et al. "Urea cycle disorders overview." In: Adam MP, et al., editors. GeneReviews. University of Washington, Seattle. Updated 2022.
- Batshaw ML, Tuchman M, Summar M, Seminara J. "A longitudinal study of urea cycle disorders." Molecular Genetics and Metabolism. 2014;113(1-2):127-130.
- Haberle J, Burlina A, Chakrapani A, et al. "Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision." Journal of Inherited Metabolic Disease. 2019;42(6):1192-1230.
- Enns GM, Berry SA, Berry GT, et al. "Survival after treatment with phenylacetate and benzoate for urea-cycle disorders." New England Journal of Medicine. 2007;356(22):2282-2292.
- Raper SE, Yudkoff M, Chirmule N, et al. "Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer." Molecular Genetics and Metabolism. 2003;80(1-2):148-158.
